Incyte Japan Secures Approval for Minjuvi Combo in Relapsed or Refractory DLBCL
Incyte Biosciences Japan G.K. has secured a significant regulatory milestone in Japan with the approval of Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The approval, granted by Japan’s Ministry of Health, Labour and Welfare (MHLW), introduces a new treatment option for patients facing one of the most aggressive forms of non-Hodgkin lymphoma, particularly those whose disease has returned or failed to respond to prior therapy.
The decision marks an important development for both Incyte and the treatment landscape in Japan, where relapsed or refractory DLBCL remains a serious clinical challenge despite progress in frontline care. While many patients with DLBCL can achieve remission with initial treatment, a substantial number either relapse or become refractory to therapy, leaving them with limited options and often poor outcomes. The approval of Minjuvi plus lenalidomide is aimed at addressing that gap by offering a non-transplant-based regimen supported by clinical data from both international and Japanese studies.
A New Option for a Difficult-to-Treat Blood Cancer
Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin lymphoma and is characterized by the rapid growth of malignant B lymphocytes. Because of its aggressive nature, DLBCL requires prompt and effective treatment. Standard first-line therapy can be successful for many patients, but the disease remains particularly difficult to manage once it relapses or proves refractory to treatment. The situation is especially challenging for patients who are not eligible for autologous stem cell transplant (ASCT), a group that often includes older patients or those with comorbidities who may not be able to tolerate intensive treatment.
For these patients, the availability of effective alternatives is critical. Incyte said the MHLW approval of Minjuvi in combination with lenalidomide provides a new therapeutic option for adults in Japan living with relapsed or refractory DLBCL, a population with historically limited treatment choices and an urgent need for additional therapies that can deliver meaningful responses.
Commenting on the approval, Yasuyuki Ishida, General Manager of Incyte Biosciences Japan, emphasized the significance of the decision for patients and families affected by this aggressive malignancy. He noted that the approval creates a new option for people in Japan with relapsed or refractory DLBCL and reaffirmed the company’s commitment to addressing critical unmet needs in difficult-to-treat cancers.
Approval Supported by International and Japanese Clinical Evidence
The Japanese approval is supported by data from two key clinical studies evaluating Minjuvi in combination with lenalidomide in patients with relapsed or refractory DLBCL who are not eligible for autologous stem cell transplant. Together, these studies provided the efficacy and safety evidence used to support the regulatory filing.
The first was the L-MIND trial (MOR208C203; NCT02399085), an international Phase II study that helped establish the clinical profile of the regimen in a global patient population. The second was the J-MIND trial (INCMOR 0208-102 Trial Part 4, Group 6; NCT04661007), a domestic Phase Ib/II study conducted in Japan to evaluate the combination in Japanese patients.
By drawing on both international and local data, the approval package gave Japanese regulators a broader picture of how the therapy performs in the target population while also providing country-specific evidence relevant to treatment in Japan. This dual-study strategy is particularly important in oncology, where local clinical data can help strengthen the case for approval and support confidence in the regimen’s applicability to Japanese patients.
L-MIND Trial Demonstrated Durable Responses in Transplant-Ineligible Patients
The L-MIND trial played a central role in building the clinical case for Minjuvi plus lenalidomide in relapsed or refractory DLBCL. This international Phase II study evaluated the regimen in patients whose disease had returned or failed to respond and who were not candidates for autologous stem cell transplant.
According to the data cited by Incyte, the trial achieved an overall response rate (ORR) of 58.8%, which served as the study’s primary endpoint. Within that response rate, 41.3% of patients achieved a complete response (CR), meaning there was no detectable evidence of disease following treatment, while 17.5% achieved a partial response (PR).
One of the most notable aspects of the L-MIND findings was the durability of response. At a median follow-up of 44 months or more, the median duration of response (mDOR) had not yet been reached, suggesting that many patients who responded to the therapy maintained their responses over an extended period. In relapsed or refractory DLBCL, where durable remissions can be difficult to achieve—especially outside of transplant—this type of long-term response signal is clinically meaningful.
The L-MIND results helped position Minjuvi plus lenalidomide as a potentially valuable option for transplant-ineligible patients by showing not only that the regimen could induce responses, but also that a substantial portion of those responses could be deep and durable.
J-MIND Trial Reinforced Efficacy in Japanese Patients
The Japanese approval was also supported by the J-MIND trial, which evaluated the same regimen in a domestic Japanese patient population. This study provided local evidence on efficacy and safety and is particularly important because regulatory agencies often place strong value on data generated in the population that will ultimately receive the therapy.
Based on an independent review committee assessment with a data cutoff date of August 31, 2023, the J-MIND trial showed a response rate of 71.4%, which is numerically higher than the ORR reported in the L-MIND study. Within that overall response rate, 45.2% of patients achieved a complete response and 26.2% achieved a partial response.
These findings are notable for several reasons. First, they reinforce the activity of the Minjuvi-lenalidomide combination in relapsed or refractory DLBCL. Second, they suggest that the regimen can produce high response rates in Japanese patients, supporting the relevance of the treatment for use in Japan’s clinical setting. And third, the complete response rate of more than 45% highlights the potential for the therapy to induce substantial tumor reduction or disease clearance in a population with limited alternatives.
Taken together, the L-MIND and J-MIND data provide a consistent picture of clinical benefit in a difficult-to-treat patient group. While cross-trial comparisons should always be made cautiously, the results from both studies point to meaningful anti-lymphoma activity and support the rationale for bringing the regimen to patients in Japan.
Safety Profile Considered Manageable
As with any cancer treatment, efficacy is only one side of the equation; safety and tolerability are equally important, especially in a relapsed or refractory population that may already be medically fragile. In the studies supporting Minjuvi’s approval, the main adverse events included neutropenia and thrombocytopenia.
Neutropenia, a reduction in neutrophils, can increase the risk of infection and is a common concern with many hematologic cancer therapies. Thrombocytopenia, a low platelet count, can increase the risk of bruising or bleeding. These side effects are well recognized in oncology practice and often require careful monitoring, dose modifications, supportive care, or temporary treatment interruptions depending on severity.
Incyte said that overall, Minjuvi in combination with lenalidomide demonstrated clinically meaningful responses with manageable side effects in the clinical trials. That characterization is important because treatment decisions in relapsed or refractory DLBCL often require balancing efficacy with tolerability, particularly in patients who may not be eligible for more intensive interventions such as stem cell transplant.
The manageable safety profile observed in the studies likely contributed to the MHLW’s decision to approve the regimen, as regulators evaluate not only whether a treatment works but whether its risks are acceptable relative to the seriousness of the disease and the availability of alternative therapies.
Why This Approval Matters in DLBCL
The approval of Minjuvi plus lenalidomide is significant because relapsed or refractory DLBCL remains one of the more difficult settings in lymphoma care. Even though first-line treatment can be curative for many patients, those who relapse often face a narrowing set of options. In younger and fitter patients, autologous stem cell transplant has traditionally been an important approach after salvage therapy. But many patients are not candidates for transplant due to age, underlying health conditions, disease biology, or inadequate response to prior treatment.
That leaves a sizable group of patients in need of alternative therapies capable of controlling the disease and, ideally, delivering deep and durable responses. The Minjuvi-lenalidomide combination is designed for precisely this setting. By targeting CD19 through tafasitamab while combining with the immunomodulatory effects of lenalidomide, the regimen offers a biologically distinct treatment option that differs from conventional chemotherapy-based approaches.
For clinicians in Japan, the approval expands the treatment toolkit for relapsed or refractory DLBCL and provides another option for patients who are not eligible for transplant. In practical terms, that may help physicians tailor therapy more effectively based on a patient’s age, fitness, prior treatment history, and disease status.
A Second Approval for Minjuvi in Japan
This latest regulatory decision also represents an important commercial and strategic milestone for Incyte in Japan because it is the second approval for Minjuvi in the country. The therapy had already received approval from the MHLW in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma in the second-line and later setting.
That earlier approval established Minjuvi’s presence in Japan’s hematology-oncology market and gave Incyte an initial commercial foothold for the product in B-cell malignancies. The new DLBCL indication broadens that footprint and strengthens the drug’s role within the company’s lymphoma portfolio.
From a lifecycle perspective, expanding Minjuvi across multiple lymphoma subtypes is strategically important. Each new approval increases the therapy’s relevance to hematologists and oncologists, deepens the body of clinical experience with the drug, and broadens the number of patients who may potentially benefit from it. In Japan, where the company is continuing to build its oncology presence, the DLBCL approval could help further establish Incyte as a meaningful player in hematologic malignancies.
Strengthening Incyte’s Oncology Presence in Japan
The approval also reflects Incyte’s broader efforts to expand its oncology business in Japan through targeted therapies and partnerships that address areas of high unmet need. Japan remains one of the world’s most important pharmaceutical markets, and securing MHLW approval is a major milestone for any oncology product seeking to establish a durable presence there.
For Incyte Biosciences Japan, bringing Minjuvi to patients with relapsed or refractory DLBCL aligns with the company’s strategy of addressing serious hematologic cancers where improved treatment options are needed. It also highlights the importance of combining global clinical development with country-specific evidence generation, as seen in the use of both the L-MIND and J-MIND studies to support the approval.
As the product moves into the Japanese market for DLBCL, attention will likely turn to launch execution, physician education, reimbursement, and uptake among transplant-ineligible patients. In oncology, approval is only the first step; commercial success depends on ensuring that clinicians understand where the therapy fits in treatment pathways and that eligible patients can access it in a timely manner.
With the MHLW’s approval now secured, Incyte has added another important indication to Minjuvi’s label in Japan and expanded the treatment landscape for adults with relapsed or refractory DLBCL. For patients whose disease has returned after prior therapy—or whose lymphoma has failed to respond at all—the approval offers a new therapeutic option backed by evidence from both international and Japanese studies.
The L-MIND and J-MIND trials showed encouraging response rates, including meaningful complete response rates, in a patient population that often has few good alternatives. Just as importantly, the combination demonstrated a safety profile that appears manageable within the context of relapsed or refractory lymphoma care. Those factors together made a compelling case for approval and could position Minjuvi plus lenalidomide as an important treatment option for transplant-ineligible DLBCL patients in Japan.
For Incyte, the decision further reinforces Minjuvi’s role in B-cell lymphoma treatment and strengthens the company’s oncology franchise in one of the world’s key pharmaceutical markets. For clinicians and patients, it provides another potential pathway forward in a disease setting where additional options are urgently needed.
As Japan’s lymphoma treatment landscape continues to evolve—with targeted therapies, cellular therapies, and antibody-based regimens all reshaping care—the approval of Minjuvi plus lenalidomide adds another important choice to the mix. In a cancer as aggressive as relapsed or refractory DLBCL, having more effective and accessible options can make a meaningful difference, and Incyte’s latest approval is aimed squarely at meeting that need.
About L-MIND
L-MIND was a single-arm, open-label Phase 2 study evaluating tafasitamab in combination with lenalidomide in adults with relapsed or refractory diffuse large B-cell lymphoma who had received at least one, but no more than three, prior lines of therapy (including an anti-CD20 therapy such as rituximab) and who were not eligible for, or refused, high-dose chemotherapy followed by autologous stem cell transplant.2 The primary endpoint was overall response rate; secondary endpoints included duration of response, progression-free survival, and overall survival.2
For more information about the study, please visit https://clinicaltrials.gov/study/NCT02399085.
About J-MIND
J-MIND Trial Part 4 (Group 6) (NCT04661007) is a Japanese Phase Ib/II clinical trial evaluating the efficacy and safety of tafasitamab in combination with lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Patients enrolled in this trial had received one to three prior systemic therapies, including CD20-targeted therapy, and were deemed by the principal investigator to be ineligible for or unresponsive to autologous hematopoietic stem cell transplantation.4
The primary endpoint of this trial was the objective response rate (ORR) as assessed by an independent review committee based on the Lugano criteria; secondary endpoints included complete response (CR), progression-free survival (PFS), and overall survival (OS).4
For more information about the study, please visit https://clinicaltrials.gov/study/NCT04661007.
About Minjuvi® (tafasitamab)
Minjuvi® (tafasitamab) is a humanized, Fc-modified, cytolytic CD19-targeting monoclonal antibody. Tafasitamab incorporates an XmAb® engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanisms, including antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). Incyte licenses exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc.
In the U.S., Monjuvi® (tafasitamab-cxix) received accelerated approval in the United States in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low-grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).6 Additionally, Monjuvi is approved by the U.S. FDA in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).6
In Europe, Minjuvi (tafasitamab) received conditional marketing authorization from the European Medicines Agency in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory DLBCL who are not eligible for ASCT.7 Additionally, Minjuvi is approved in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1–3a) after at least one line of systemic therapy in Europe.7
In Japan, Minjuvi is approved in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in Japan.8 Minjuvi is also approved in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL).
